Insider Activity: Genpact CHRO Acquires at $31.50, Sells at $42.58
Rhea-AI Filing Summary
Insider transactions by Genpact Ltd (G): Senior Vice President and CHRO Piyush Mehta executed multiple transactions on 09/12/2025. He acquired 50,000 common shares at $31.50, and sold 50,000 shares and 26,902 shares at weighted-average prices of $42.58 (sales ranged from $42.42 to $42.73 and $42.42 to $42.70 respectively). After these transactions he beneficially owns 134,880 common shares. The filing notes he holds 10,222 shares under the ESPP (including 284 shares acquired since his prior Form 4). The Form 4 was signed by an attorney-in-fact on 09/15/2025.
Positive
- Realized gain potential: Exercised 50,000 shares at $31.50 and sold shares at a weighted-average of $42.58, indicating a per-share spread of about $11.08 on shares sold.
- Continued ownership: Reporting person retains 134,880 shares after transactions, maintaining significant ongoing ownership.
- ESPP participation: Holds 10,222 shares under the Genpact ESPP, including 284 shares acquired since prior Form 4.
Negative
- Net reduction in holdings: Total common shares beneficially owned decreased from 211,782 to 134,880 following sales of 76,902 shares.
- Insider sales disclosed: Two sales on 09/12/2025 (50,000 and 26,902 shares) may be viewed by some investors as liquidity-driven reducing insider share count.
Insights
TL;DR: Insider exercised equity at $31.50 then sold portions at ~42.58, realizing gains; overall holdings decreased to 134,880 shares.
The transactions show a typical option exercise followed by partial disposition to monetize gains. Acquisition of 50,000 shares at $31.50 and immediate sales at a weighted-average of $42.58 imply a realized pre-tax spread of roughly $11.08 per share on those sold, though exact realized gain depends on which specific shares were sold. The reporting person still retains a meaningful stake (134,880 shares) and continues participation in the ESPP (10,222 shares), indicating retained exposure while capturing liquidity.
TL;DR: Transactions were disclosed in compliance with Section 16; no regulatory or governance concerns evident from the filing.
The Form 4 provides required detail including transaction codes, weighted-average sale price ranges, ESPP holdings, and a signed filing. The record includes an attorney-in-fact signature and explanations for price ranges and vesting history of the option. There are no disclosed exceptions, amendments, or unusual arrangements in the filing text provided.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Employee Stock Option (Right to Buy) | 50,000 | $0.00 | -- |
| Exercise | Common Shares | 50,000 | $31.50 | $1.57M |
| Sale | Common Shares | 50,000 | $42.58 | $2.13M |
| Sale | Common Shares | 26,902 | $42.58 | $1.15M |
Footnotes (1)
- Includes 284 shares acquired under the Genpact Employee Stock Purchase Plan ("ESPP") since the reporting person's Form 4 filed on March 13, 2025. The reporting person currently holds a total of 10,222 shares under the ESPP. The price in Column 4 is a weighted average price. The actual sales prices for these transactions ranged from $42.42 to $42.73. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. The price in Column 4 is a weighted average price. The actual sales prices for these transactions ranged from $42.42 to $42.70. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. The option vested 50% on April 2, 2021 and the remainder on April 2, 2023.
